Some P2X7 selective antagonists that can penetrate the blood–brain barrier (BBB) exhibit therapeutic effects on depression in a chronic stress model by inhibiting the activation of P2X7–NLRP3–IL-1β pathway, reducing the immune inflammatory effect of microglia cells and the neuroinflammation of CNS [41]. Here, P2RX7 is linked to depressive symptom measurement.